Pfizer Inc Cdr Stock Fundamentals
| PFE Stock | 12.17 0.10 0.83% |
Pfizer Inc CDR fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.
At this time, Pfizer's Income Tax Expense is very stable compared to the past year. Pfizer | Select Account or Indicator |
Pfizer Inc CDR Company Return On Equity Analysis
Pfizer's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pfizer Return On Equity | 0.0454 |
Most of Pfizer's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc CDR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Pfizer Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Pfizer Inc CDR has a Return On Equity of 0.0454. This is 100.19% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all Canada stocks is 114.65% lower than that of the firm.
Pfizer Inc CDR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pfizer competition to find correlations between indicators driving Pfizer's intrinsic value. More Info.Pfizer Inc CDR is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pfizer Inc CDR is roughly 1.37 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pfizer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pfizer's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Pfizer Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in return on equity category among its peers.
Pfizer Fundamentals
| Return On Equity | 0.0454 | ||||
| Return On Asset | 0.0331 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 287.47 B | ||||
| Shares Outstanding | 16.69 B | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 3.47 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 18.37 B | ||||
| Net Income | 2.12 B | ||||
| Total Debt | 10.35 B | ||||
| Book Value Per Share | 16.29 X | ||||
| Cash Flow From Operations | 12.04 B | ||||
| Earnings Per Share | 0.36 X | ||||
| Price To Earnings To Growth | 0.18 X | ||||
| Number Of Employees | 88 K | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 205.74 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Annual Yield | 0.06 % | ||||
| Net Asset | 226.5 B | ||||
| Last Dividend Paid | 1.67 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc CDR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc CDR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 58.5 B | 71 B | |
| Cost Of Revenue | 25 B | 22.1 B |
Pair Trading with Pfizer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.Moving together with Pfizer Stock
Moving against Pfizer Stock
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Pfizer Stock
Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.